康弘药业(002773) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥1,170,203,783.10, representing a 4.75% increase year-over-year[5] - Net profit attributable to shareholders was ¥303,207,431.06, up 7.71% compared to the same period last year[5] - The basic earnings per share for the period was ¥0.33, which is a 6.45% increase year-over-year[5] - Total operating revenue for the current period reached ¥3,623,865,721.06, an increase of 6.2% compared to ¥3,411,293,193.61 in the previous period[22] - Net profit for the current period was ¥1,021,124,394.93, representing a growth of 5.8% from ¥964,889,830.03 in the previous period[23] - Earnings per share (EPS) for the current period was ¥1.12, compared to ¥1.06 in the previous period, indicating an increase of 5.7%[23] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥9,870,033,859.62, reflecting a 5.65% increase from the end of the previous year[5] - Total assets increased to ¥9,870,033,859.62 from ¥9,341,936,339.67, marking a growth of 5.7%[21] - Total liabilities rose to ¥719,980,060.47, up from ¥695,069,259.77, reflecting an increase of 3.7%[21] - The total equity attributable to shareholders of the parent company was ¥9,166,361,019.00, compared to ¥8,653,202,130.15, an increase of 5.9%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,408,275,688.02, an increase of 12.26%[5] - Operating cash flow for the current period was ¥1,408,275,688.02, an increase of 12.2% compared to ¥1,254,467,611.62 in the previous period[24] - Cash inflow from sales of goods and services was ¥3,867,965,865.99, compared to ¥3,649,309,553.09 in the previous period, reflecting a growth of 6.0%[24] - Total cash outflow from operating activities was ¥2,578,063,329.64, an increase from ¥2,430,058,668.41 in the previous period[24] - Cash flow from financing activities resulted in a net outflow of -¥519,112,267.76, compared to -¥343,198,374.48 in the previous period[25] Investments and Financial Activities - Investment income from financial products was recorded at ¥11,533,310.23, classified as regular income due to its frequency and relevance to business operations[10] - The company reported a financial income of ¥41,612,234.52, down from ¥47,008,183.20, a decline of 11.4%[22] - The company reported a significant increase of 269.90% in prepayments, totaling ¥42,378,031.18[12] - Total cash inflow from investment activities was ¥3,252,470,799.99, up from ¥2,132,043,970.54 in the previous period, representing a 52.5% increase[24] - Net cash flow from investment activities was -¥2,732,633,098.12, worsening from -¥2,316,936,761.18 in the previous period[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 23,995[15] - Chengdu Kanghong Technology Industry (Group) Co., Ltd. holds 31.70% of shares, totaling 292,014,900 shares[15] - The top ten shareholders include Chengdu Kanghong Technology Industry (Group) Co., Ltd. and several individual shareholders, with no participation in margin trading reported[16] Research and Development - Research and development expenses for the current period were ¥334,157,560.21, slightly down from ¥342,158,088.75, a decrease of 2.4%[22] - The company received a drug registration certificate for Lifi Shite eye drops from the National Medical Products Administration[17] - The company’s subsidiary received clinical trial approval for KH813 injection from the National Medical Products Administration[17] - The company completed the absorption merger of its wholly-owned subsidiary Sichuan Jishengtang Pharmaceutical Co., Ltd.[17] Current Assets and Cash Management - The company reported a total current assets of ¥7,023,154,380.28, an increase from ¥6,288,819,404.18 at the beginning of the period[19] - Cash and cash equivalents decreased to ¥3,828,071,098.77 from ¥5,689,515,722.69[19] - The ending balance of cash and cash equivalents was ¥3,781,405,973.18, an increase from ¥3,263,580,439.45 in the previous period[25] - The company’s cash and cash equivalents decreased by ¥1,844,021,273.38 during the period, compared to a decrease of ¥1,406,413,781.15 in the previous period[25]